

Regular Meeting of the
Santa Clara County Health Authority
Pharmacy and Therapeutics (P&T) Committee

Thursday, April 30, 2020, 6:00-8:00 PM
 Santa Clara Family Health Plan
 6201 San Ignacio Ave, San Jose, CA 95119

Via Teleconference
 (669) 900-6833
 Meeting ID: 966 4888 0811
 Password: 8i.b+p27

AGENDA

- | | | | |
|--|---------------|------|--------|
| 1. Roll Call / Establish Quorum | Dr. Lin | 6:00 | 5 min |
| 2. Public Comment
Members of the public may speak to any item not on the agenda; two minutes per speaker. The Committee reserves the right to limit the duration of public comment period to 30 minutes. | Dr. Lin | 6:05 | 5 min |
| 3. Open Meeting Minutes
Review Santa Clara Family Health Plan (SCFHP)
4Q2019 P&T Open Minutes
Possible Action: Approve SCFHP P&T Open Minutes | Dr. Lin | 6:10 | 2 min |
| 4. Standing Agenda Items | | | |
| a. Chief Medical Officer Health Plan Updates | Dr. Nakahira | 6:12 | 5 min |
| b. Plan/Global Medi-Cal Drug Use Review | Dr. Otomo | 6:17 | 3 min |
| c. Appeals & Grievance 4Q2019 Report | Mr. Breakbill | 6:20 | 3 min |
| d. Annual Pharmacy Policy Review | Dr. Huynh | 6:23 | 10 min |
| i. <u>New or Revised Policy</u>
PH.10 Cal MediConnect Part D Transition (2020) | | | |
| ii. <u>Annual Review</u> | | | |
| 1. PH.01 Pharmacy and Therapeutics Committee | | | |
| 2. PH.02 Formulary Development and Guideline Management | | | |
| 3. PH.03 Prior Authorization | | | |
| 4. PH.04 Pharmacy Clinical Programs and Quality Monitoring | | | |
| 5. PH.05 Continuity of Care for Pharmacy Services | | | |
| 6. PH.06 Pharmacy Communications | | | |
| 7. PH.07 Drug Recalls | | | |
| 8. PH.08 Pain Management Drugs for Terminally Ill | | | |
| 9. PH.09 Medications for Members with Behavioral Health Conditions | | | |
| 10. PH.11 340B Program Compliance | | | |

11. PH.14 Medications for Cancer Clinical Trial
Possible Action: Approve policies

Adjourn to Closed Session

Pursuant to Welfare and Institutions Code Section 14087.36 (w)

- | | | | |
|--|--------------|------|--------|
| <p>5. Closed Meeting Minutes
Review SCFHP 4Q2019 P&T Closed Minutes
Possible Action: Approve SCFHP P&T Closed Minutes</p> | Dr. Lin | 6:33 | 2 min |
| <p>6. Metrics & Financial Updates</p> <ul style="list-style-type: none"> a. Membership Report b. Pharmacy Dashboard c. Drug Use Evaluation d. Drug Utilization & Spend | Dr. Nakahira | 6:35 | 2 min |
| | Dr. Otomo | 6:37 | 2 min |
| | Dr. Otomo | 6:39 | 1 min |
| | Dr. Huynh | 6:40 | 5 min |
| <p>7. Discussion and Recommendations for Changes to SCFHP's Cal MediConnect Formulary & Coverage Determination Criteria</p> <ul style="list-style-type: none"> a. Pharmacy Benefit Manager 4Q2019 P&T Minutes b. Pharmacy Benefit Manager 1Q2020 P&T Part D Actions <p>Possible Action: Approve MedImpact Minutes & Actions</p> | Dr. Huynh | 6:45 | 2 min |
| <p>8. Discussion and Recommendations for Changes to SCFHP's Medi-Cal & Prior Authorization Criteria</p> <ul style="list-style-type: none"> a. Old Business/Follow-Up <ul style="list-style-type: none"> i. Statin Adherence ii. Diabetes Type I & Type II b. Formulary Modifications
Possible Action: Approve recommendations c. Fee-for-Service Contract Drug List Comparability
Possible Action: Approve recommendations d. Prior Authorization Criteria <ul style="list-style-type: none"> i. <u>New or Revised Criteria</u> <ul style="list-style-type: none"> 1. Deferasirox 2. Diroximel fumarate 3. Fingolimod 4. Reauthorization - Opioids 5. Glatiramer acetate 6. Interferon beta-1a 7. Oxycodone extended-release 8. Tacrolimus ointment ii. <u>Annual Review</u> <ul style="list-style-type: none"> 1. Ambrisentan 2. General Utilization Management 3. Milnacipran 4. Raloxifene <p>Possible Action: Approve criteria</p> | Dr. Huynh | 6:47 | 3 min |
| | Dr. Otomo | 6:50 | 5 min |
| | Dr. Huynh | 6:55 | 5 min |
| | Dr. Nguyen | 7:00 | 10 min |
| <p>9. New Drugs and Class Reviews</p> <ul style="list-style-type: none"> a. <u>Informational Only</u> | Dr. Huynh | 7:10 | 2 min |

- i. Multiple sclerosis – Ozanimod
- ii. Migraine Update – Eptinezumab
- iii. Hyperlipidemia – Nexletol, Nexlizet
- iv. Acute Hepatic Porphyria – Givlaari
- v. Epilepsy – Xcopri
- vi. Ulcerative Colitis Update
- vii. Sickle Cell Anemia Update
- viii. Oncology Update
- ix. Cystic Fibrosis Update
- x. Biosimilars Update
- xi. Autoimmune updates
- xii. New derivatives/formulations/combinations
- xiii. New and Expanded Label

Reconvene in Open Session

10. Discussion Items

- a. New and Generic Pipeline

Dr. Huynh 7:12 3 min

11. Adjournment

Next meeting Thursday, June 18, 2020

Dr. Lin 7:15

Notice to the Public—Meeting Procedures

- Persons wishing to address the Committee on any item on the agenda are requested to advise the Recorder so that the Chairperson can call on them when the item comes up for discussion.
- The Committee may take other actions relating to the issues as may be determined following consideration of the matter and discussion of the possible action.
- In compliance with the Americans with Disabilities Act, those requiring accommodations in this meeting should notify Nancy Aguirre 48 hours prior to the meeting at 408-874-1835.
- To obtain a copy of any supporting document that is available, contact Nancy Aguirre at 408-874-1835. Agenda materials distributed less than 72 hours before a meeting can be inspected at the Santa Clara Family Health Plan offices at 6201 San Ignacio Ave, San Jose, CA 95119.
- This agenda and meeting documents are available at www.scfhp.com